Alexandra Ladouceur
Overview
Explore the profile of Alexandra Ladouceur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladouceur A, Jamal S, Saltman A, Himmel M, Hudson M, Pope J, et al.
ACR Open Rheumatol
. 2025 Feb;
7(2):e70002.
PMID: 39964344
Objective: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) and progression-free survival (PFS) in many types of malignancies but can result in off-target immune-related adverse events including inflammatory arthritis (ICI-associated...
2.
Ladouceur A, Barnetche T, Prey S, Dutriaux C, Gerard E, Pham-Ledard A, et al.
Joint Bone Spine
. 2024 Oct;
92(1):105795.
PMID: 39447690
Introduction: Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI treatment and after ICI discontinuation and...
3.
Zhang J, Ni R, Oke I, Calabrese C, Strouse J, Weinmann S, et al.
Rheum Dis Clin North Am
. 2024 Apr;
50(2):313-323.
PMID: 38670729
Since their introduction, immune checkpoint inhibitors have revolutionized cancer treatment by harnessing the body's own immune system as a defense against tumor growth. The downside of activating the immune system...
4.
Ladouceur A, Ezdoglian A, Sparks J, Hudson M, Jamal S, Clifford A, et al.
Rheum Dis Clin North Am
. 2024 Apr;
50(2):181-199.
PMID: 38670720
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this...
5.
Rouhi A, Jamal S, Arreola L, Moon D, Hudson M, Roberts J, et al.
J Rheumatol
. 2024 Mar;
51(5):523-528.
PMID: 38428960
Objective: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is characterized by symmetrical synovitis with pitting edema and negative rheumatoid factor (RF). It has been described in a setting of...
6.
Ladouceur A, Barnetche T, Mouterde G, Tison A, Bitoun S, Prey S, et al.
RMD Open
. 2023 Nov;
9(4).
PMID: 38030233
Objective: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data...
7.
Ladouceur A, Tessier-Cloutier B, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, et al.
Rheum Dis Clin North Am
. 2020 Jul;
46(3):533-550.
PMID: 32631602
Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased...
8.
Ladouceur A, Clarke A, Ramsey-Goldman R, Bernatsky S
Curr Opin Rheumatol
. 2019 Aug;
31(6):678-681.
PMID: 31403485
Purpose Of Review: Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared with the general population. This review summarizes the recent literature on risk of...
9.
Ladouceur A, Bernatsky S, Ramsey-Goldman R, Clarke A
Expert Rev Clin Immunol
. 2018 Sep;
14(10):793-802.
PMID: 30183456
Introduction: Numerous studies have clearly demonstrated that there is an altered cancer risk profile in patients with systemic lupus erythematous (SLE) versus the general population. This includes a higher risk...
10.
Ladouceur A, Rustamov N, Dubois J, Tessier J, Lehmann A, Descarreaux M, et al.
Neuroscience
. 2017 Oct;
387:201-213.
PMID: 29030287
The aim of the present study was to assess inhibition of pain and somatosensory-evoked potentials (SEPs) by heterotopic noxious counter-stimulation (HNCS) and by selective attention in patients with chronic non-specific...